Jeffrey Serrill, PhD has an extensive background in pharmacology, with experience working in various roles at companies such as AbbVie, Exelixis, Genentech, and more. Their research has focused on translational oncology, cellular therapeutics, and the development of technologies to improve stem cell-derived treatments for type 1 diabetes. Jeffrey holds a Doctor of Philosophy (Ph.D.) in Pharmacology from Oregon State University, along with certificates in Bioscience Management and College and University Teaching.
May, 2022 - present